Almirall acquires an Allergan US portfolio of dermatology products.

Almirall entered into a definitive agreement to acquire an Allergan U.S. portfolio of mature and growth brands for acne and dermatoses, including a new innovative NCE, Seysara (sarecycline) for the oral treatment of acne. The closing of this transaction is expected in Q4 2018 With this strategic and very focused transaction, Almirall significantly reinforces its position in the largest dermatology market in the world.All products will be distributed through our US platform and team, which has deep knowledge of the oral acne market and the acquired portfolio. They will provide critical mass to launch KX2-391, which has the potential to become the new standard of care in actinic keratosis.The acquired portfolio generated net sales of $70 millioin in the first half of 2018 and offers medium to long-term growth potential. Almirall expects peak sales of Seysara (sarecycline) from $150 million to $200 million.The acquisition has been announced for a cash consideration of $550 million at closing.